MXPA04004026A - Conjugados polimericos de inhibidores de la proteina quinasa c. - Google Patents

Conjugados polimericos de inhibidores de la proteina quinasa c.

Info

Publication number
MXPA04004026A
MXPA04004026A MXPA04004026A MXPA04004026A MXPA04004026A MX PA04004026 A MXPA04004026 A MX PA04004026A MX PA04004026 A MXPA04004026 A MX PA04004026A MX PA04004026 A MXPA04004026 A MX PA04004026A MX PA04004026 A MXPA04004026 A MX PA04004026A
Authority
MX
Mexico
Prior art keywords
polymer
inhibitors
protein kinase
pkc inhibitor
polymer conjugates
Prior art date
Application number
MXPA04004026A
Other languages
English (en)
Inventor
David Bentley Michael
Original Assignee
Nektar Therapeutics Al Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics Al Corp
Publication of MXPA04004026A publication Critical patent/MXPA04004026A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion proporciona conjugados polimericos de inhibidores de la proteina quinasa C (PKC) que comprenden un polimero tal como poli(etilen glicol) fijado covalentemente a un inhibidor de PKC, tal como una molecula de bisindolilmaleimida. El enlace entre el polimero y el inhibidor de PKC es preferiblemente degradable hidroliticamente. La invencion tambien incluye una composicion farmaceutica que comprende un conjugado polimerico de un inhibidor de PKC y un metodo para tratar cualquier condicion correspondiente a un inhibidor de PKC al administrar un conjugado polimerico de la invencion.
MXPA04004026A 2001-10-29 2002-10-29 Conjugados polimericos de inhibidores de la proteina quinasa c. MXPA04004026A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34053501P 2001-10-29 2001-10-29
PCT/US2002/034666 WO2003037384A2 (en) 2001-10-29 2002-10-29 Polymer conjugates of protein kinase c inhibitors

Publications (1)

Publication Number Publication Date
MXPA04004026A true MXPA04004026A (es) 2004-07-08

Family

ID=23333806

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004026A MXPA04004026A (es) 2001-10-29 2002-10-29 Conjugados polimericos de inhibidores de la proteina quinasa c.

Country Status (8)

Country Link
US (1) US20030143185A1 (es)
EP (1) EP1441772A2 (es)
JP (1) JP2005508365A (es)
KR (1) KR20050040832A (es)
AU (1) AU2002342193B2 (es)
CA (1) CA2463580A1 (es)
MX (1) MXPA04004026A (es)
WO (1) WO2003037384A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2569262T3 (es) 2001-10-18 2016-05-09 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
US20050004038A1 (en) * 2003-06-27 2005-01-06 Lyon Robert P. Bivalent inhibitors of Glutathione-S-Transferases
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
AU2004274489B2 (en) * 2003-09-17 2011-06-09 Nektar Therapeutics Multi-arm polymer prodrugs
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1725572B1 (de) 2003-11-05 2017-05-31 AGCT GmbH Makromolekulare nukleotidverbindungen und methoden zu deren anwendung
EP2604282B1 (en) * 2003-12-16 2019-06-19 Nektar Therapeutics Method for preparing of monodisperse oligo ethylene glycol
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
CN101583380B (zh) 2006-11-30 2013-07-10 尼克塔治疗公司 用于制备聚合物轭合物的方法
RU2009133793A (ru) 2007-02-09 2011-03-20 Энзон Фармасьютикалз, Инк. (Us) Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи
US8748648B2 (en) * 2007-09-06 2014-06-10 Nektar Therapeutics Oligomer-calcium channel blocker conjugates
US20110009446A1 (en) * 2008-01-11 2011-01-13 Nektar Therapeutics Oligomer-guanidine class conjugates
EP2331140B1 (en) 2008-08-11 2018-07-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
SI2349346T1 (sl) 2008-09-23 2019-12-31 Nektar Therapeutics Postopek metronomskega doziranja s kamptotekinskim predzdravilom (npr. PEG-irinotekan)
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2010120388A1 (en) * 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2010120387A1 (en) * 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
DE102010049607A1 (de) 2009-10-26 2011-06-30 Becker, Claus, Prof., 76470 Konjugate von Nukleotiden und Methoden zu deren Anwendung
PL2621496T5 (pl) 2010-09-30 2019-05-31 Astrazeneca Ab Krystaliczny koniugat naloksol-peg
US20140371258A1 (en) 2010-12-17 2014-12-18 Nektar Therapeutics Water-Soluble Polymer Conjugates of Topotecan
EP2654795B1 (en) 2010-12-21 2018-03-07 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
CN105037398B (zh) * 2014-04-16 2017-10-24 深圳永泽医药股份有限公司 一种Bcr‑Abl双倍体抑制剂及其制备方法和用途
JP2017511348A (ja) * 2014-04-16 2017-04-20 成都大学 Ｂｃｒ−Ａｂｌ二倍体の阻害剤、その調製方法及びその用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278989B6 (sk) * 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
US6673364B1 (en) * 1995-06-07 2004-01-06 The University Of British Columbia Liposome having an exchangeable component
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
EA001450B1 (ru) * 1996-05-01 2001-04-23 Эли Лилли Энд Компани Галогензамещенные ингибиторы протеинкиназы с
PE91598A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6284783B1 (en) * 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6559164B1 (en) * 1999-10-12 2003-05-06 Hoffmann-La Roche Inc. Substituted pyrroles suitable for continuous infusion
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
CA2431166A1 (en) * 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Indazolyl-substituted pyrroline compounds as kinase inhibitors

Also Published As

Publication number Publication date
US20030143185A1 (en) 2003-07-31
AU2002342193C1 (en) 2003-05-12
KR20050040832A (ko) 2005-05-03
JP2005508365A (ja) 2005-03-31
WO2003037384A3 (en) 2003-08-28
AU2002342193B2 (en) 2006-10-26
CA2463580A1 (en) 2003-05-08
EP1441772A2 (en) 2004-08-04
WO2003037384A2 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
MXPA04004026A (es) Conjugados polimericos de inhibidores de la proteina quinasa c.
WO2003032990A3 (en) Polymer conjugates of opioid antagonists
CY1121314T1 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
WO1997029779A3 (en) EGF-Genistein conjugates for the treatment of cancer
WO2004110358A3 (en) Polymeric conjugates for tissue activated drug delivery
BR0208373A (pt) Inibidores da tirosina cinase
RS20050263A (en) Polymer conjugates with decreased antigenicity,methods of preparation and uses thereof
BRPI0412671A (pt) conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
HK1048990A1 (en) Novel compounds.
WO2008076333A3 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
ATE253063T1 (de) 5-ht1f-agonisten
WO2005023294A3 (en) Polyacetal drug conjugates as release system
BR0208741A (pt) Derivados de piperidina
PT1017675E (pt) Derivados da camtotecina altamente lipofilos
BR0207978A (pt) N-but-3enil norbuprenorfina e métodos de uso
NO20021367D0 (no) Indolyl-3-glyoksylsyrederivater som har terapeutisk verdifulle egenskaper
SE0101932D0 (sv) Pharmaceutical combinations
UA82983C2 (ru) Полимерные коньюгаты найбластина и способы их использования
CA2535210A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
WO2000078795A3 (en) Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1)
WO2005027828A3 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
WO2006089228A3 (en) Conjugates of an epo moiety and a polymer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal